{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(2)"],"submitter":["Duminuco A"],"pubmed_abstract":["<h4>Background</h4>Immune system impairment is frequently reported in patients affected by hemoglobinopathies due to various mechanisms, including iron accumulation, antigenic stimulation due to numerous transfusions, chronic hemolysis, and a general hyperinflammatory state. For these reasons, the antigenic immune response after a vaccine risks being ineffective.<h4>Methods</h4>We evaluated the anti-spike IgG production after two doses of vaccine for SARS-CoV-2 in patients affected by hemoglobinopathies.<h4>Results</h4>All 114 enrolled patients (100%) developed adequate antibody production, with a median value of serum IgG of 2184.4 BAU/mL (IQR 1127.4-3502.9). The amount of antibody was unrelated to any other clinical characteristics evaluated, including transfusion dependence or non-trans"],"journal":["Vaccines"],"pagination":["111"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11860232"],"repository":["biostudies-literature"],"pubmed_title":["Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience."],"pmcid":["PMC11860232"],"pubmed_authors":["Raimondo FD","Tibullo D","Rosso R","Bulla A","La Spina E","Duminuco A","Ximenes B","Giallongo C","Palumbo GA","Romeo MA","Romano A","Cambria D"],"additional_accession":[]},"is_claimable":false,"name":"Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.","description":"<h4>Background</h4>Immune system impairment is frequently reported in patients affected by hemoglobinopathies due to various mechanisms, including iron accumulation, antigenic stimulation due to numerous transfusions, chronic hemolysis, and a general hyperinflammatory state. For these reasons, the antigenic immune response after a vaccine risks being ineffective.<h4>Methods</h4>We evaluated the anti-spike IgG production after two doses of vaccine for SARS-CoV-2 in patients affected by hemoglobinopathies.<h4>Results</h4>All 114 enrolled patients (100%) developed adequate antibody production, with a median value of serum IgG of 2184.4 BAU/mL (IQR 1127.4-3502.9). The amount of antibody was unrelated to any other clinical characteristics evaluated, including transfusion dependence or non-trans","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-22T18:59:28.717Z","creation":"2025-04-06T02:37:38.483Z"},"accession":"S-EPMC11860232","cross_references":{"pubmed":["40006658"],"doi":["10.3390/vaccines13020111"]}}